PGx Medical
PGx Medical provides pharmacogenetic testing through its Metabolic Validation Program, helping long-term care communities, clinics, and pharmacies align medication regimens with elderly patients' genetic profiles to reduce adverse drug reactions and polypharmacy.
- Company typePrivate
- Founded2010
- HeadquartersOklahoma City, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What PGx Medical does
PGx Medical is a privately held pharmacogenetic testing company founded in 2010 and headquartered in Oklahoma City, Oklahoma. The company's core offering is the Metabolic Validation Program, a one-time cheek swab (buccal sample) diagnostic test that analyzes cytochrome P450 enzymes (including CYP2D6) to determine how patients metabolize medications. Results are returned within 48–72 hours as personalized medication reports with actionable prescribing recommendations. PGx Medical positions itself as a consultant and educator rather than a laboratory, providing implementation support, clinical training, and ongoing interpretation guidance to its customers.
The company's primary market is the aging services vertical, specifically long-term care communities (nursing homes, assisted living, memory care, skilled nursing, independent living), with additional reach into clinics and pharmacies serving Medicare-eligible populations. Go-to-market combines direct enterprise sales to LTC facilities with channel partnerships through state aging services organizations (LeadingAge Oklahoma, LeadingAge Minnesota), the Oklahoma Department of Veterans Affairs, and consultant pharmacy networks. Key named partners and customers include Parks Edge Nursing & Rehab, Cordell Christian Home, Cherokee Manor, Fairview Fellowship Home, Wellington Parke Retirement Community, and PharmCareOK.
Revenue is generated primarily through Medicare Part B reimbursement for each diagnostic test (with Medicaid coverage in select states) and secondary consulting and implementation services. Pricing is usage-based with no out-of-pocket cost to Medicare Part B beneficiaries. The company also markets a UTI diagnostic testing category alongside its pharmacogenomics offering. Leadership includes founder and President Clay Bullard and Director of Education Kelly Burleson. The company has 11–50 employees and no disclosed institutional funding.
PGx Medical firmographics
Firmographics- Name
- PGx Medical
- Legal name
- PGx Medical
- Website
- https://pgxmed.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PGx Medical provides pharmacogenetic testing through its Metabolic Validation Program, helping long-term care communities, clinics, and pharmacies align medication regimens with elderly patients' genetic profiles to reduce adverse drug reactions and polypharmacy.
- Ownership category
- akta.pro rank
PGx Medical industry classification
Industry- Product category
- Pharmacogenetic Testing Services
- NAICS
- Medical Laboratories (621511), Services for the Elderly and Persons with Disabilities (624120)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industries
- Pharmacogenomics-Informed Medication Optimization Support (HSABALAO), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Medication Management Coordination & Polypharmacy Review (HLADALAE)
Keywords
Where PGx Medical is headquartered
LocationHeadquarters
- HQ city
- Oklahoma City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PGx Medical business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Medicare Part B Reimbursement: The pharmacogenetic test is covered by Medicare Part B, providing reimbursement for the diagnostic testing service. Medicaid covers the cost in select states.
- Consulting and Implementation Services: PGx Medical provides consultation and implementation services to long-term care communities, clinics, and pharmacies for implementing pharmacogenetic testing programs.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Medicare Part B covered pharmacogenetic testing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
PGx Medical product offering
Product offeringCore offering
PGx Medical delivers pharmacogenetic testing through its Metabolic Validation Program — a one-time cheek swab diagnostic that analyzes a patient's genetic profile (including CYP450 enzymes) to determine how they metabolize medications. The company sells this testing program along with implementation support, staff education, and ongoing consultation to long-term care communities, clinics, and consultant pharmacies serving elderly populations. The service is reimbursable under Medicare Part B and supported by Medicaid in select states, and is targeted at reducing adverse drug reactions, polypharmacy, falls, and antipsychotic overuse in older adults.
Product overview
PGx Medical offers a single core diagnostic product — the Pharmacogenetic Testing service, also referred to as the Metabolic Validation Program. This is a one-time cheek swab test that analyzes a patient's genetic profile to determine how their body metabolizes medications. The test results help healthcare providers align current and future medications with each person's unique genetic profile, addressing clinical concerns such as falls, dementia, sleep, pain, medication management, and overall staff efficiencies. The company also provides implementation support, education, and consulting services to help long-term care communities, clinics, and pharmacies integrate the testing into their workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Metabolic Validation Program: The company's primary pharmacogenetic testing program that aligns current and future medications with each person's unique genetic profile
Products and services
- Metabolic Validation Program (Pharmacogenetic Testing) A one-time cheek swab pharmacogenetic testing program that analyzes a patient's genetic profile, including CYP450 enzymes such as CYP2D6, to classify them as poor, intermediate, extensive, or ultra-rapid metabolizers. The test produces a personalized medication report with actionable dosing and drug recommendations, delivered within 48–72 hours, and is sold to long-term care communities, clinics, and consultant pharmacies serving elderly populations. Covered by Medicare Part B with no out-of-pocket cost to residents, and by Medicaid in select states.
- Consulting and Implementation Services Professional services offering that helps long-term care communities, clinics, and pharmacies implement pharmacogenetic testing programs end-to-end — including staff training, testing administration, result interpretation, and ongoing consultation to support medication regimen changes. Targeted at facility administrators, directors of nursing, medical directors, and consultant pharmacists.
Quantifiable outcome
- 90% of patients need medication adjustment after testing
- +3 more outcomes
Companies that use PGx Medical
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
PGx Medical technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
PGx Medical partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core and minor.
- Oklahoma Department of Veterans AffairscoreState agency partnership to reduce medication costs and provide medication management information to physicians, nurses, and clinics across Oklahoma's 7 VA homes.
- LeadingAge MinnesotacorePartnership with LeadingAge Minnesota to announce pharmacogenetic testing program availability for member aging services communities in Minnesota.
- Dr. Linda ShellcoreDr. Linda Shell RN partnered with PGx Medical to launch a Person-Centered Care Pharmacogenetics Pilot Program for long-term care communities. The pilot program offers streamlined implementation for independent, assisted, skilled, memory care, and home health settings.
- LeadingAge OklahomacoreStrategic partnership with LeadingAge Oklahoma to promote pharmacogenetic testing to member facilities. PGx Medical President Clay Bullard spoke at the Spring Conference. The partnership focuses on education and implementation of the Metabolic Validation Program for aging services providers in Oklahoma.
- Dr. Jami Benton, MDcoreFamily practice physician and Medical Director at Cherokee Manor and Fairview Fellowship Home. Uses pharmacogenetic testing in clinic practice and nursing home patients. Testimonial advocate for the technology.
- Cordell Christian HomeminorLong-term care facility that implemented Metabolic Validation testing. Achieved first year without 'unnecessary drug' F-tag during state survey after implementing the program.
- Parks Edge Nursing & RehabcoreEarly partner that implemented the Metabolic Validation Program. PGx Medical consultant met with the facility, provided testing supplies, and helped interpret results. Facility was able to test 75% of eligible residents in a few hours.
- PharmCareOK (Garrett Huxall, Pharm.D)corePharmacy consulting company led by Garrett Huxall that utilizes pharmacogenetics testing to recommend proper medication therapy in nursing home settings. Provides case studies demonstrating program effectiveness.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
PGx Medical competitors and assessment
Company assessmentDirect peers
- Myriad Genetics (GeneSight): Myriad's GeneSight Psychotropic and Pain tests are the most commercially established pharmacogenomics panels in the U.S., directly competing with PGx Medical's Metabolic Validation Program. Like PGx, GeneSight promotes use among prescribers managing polypharmacy and psychiatric medications, though it is currently focused on outpatient psychiatric clinics rather than LTC facilities — making it the closest direct competitor for the same clinical use cases.
- Genomind: Genomind offers the Genecept Assay and PGx tools aimed at clinicians treating depression, anxiety, and other psychiatric conditions — the exact medication classes PGx Medical's program targets. It competes head-to-head on CYP450-based mental-health pharmacogenomics and shares PGx Medical's prescriber-education-driven sales model.
- Molecular Health: Molecular Health provides molecular decision-support products such as MH Guide that translate genomic data into clinical prescribing guidance, including for oncology and drug safety. Its PGx decision-support overlap with PGx Medical's interpretation-of-genetic-results positioning makes it a comparable clinical-decision-support peer in the same pharmacogenomics category.
- Coriell Life Sciences: Coriell Life Sciences offers pharmacogenomic interpretation and clinical decision support for medication management, including medication safety and polypharmacy initiatives. It targets employer, payer, and provider populations with CYP450 and broader PGx panels — overlapping with PGx Medical's drug-metabolism and medication-optimization focus.
- YouScript / GenieMD: YouScript (now part of GenieMD) provides pharmacogenomics-based medication decision-support software aimed at clinicians managing polypharmacy and adverse drug events. It is functionally the same product category as PGx Medical — using PGx results to flag drug-gene interactions and guide prescribing — and is sold to provider systems and payers.
Broad incumbents
- Omnicare (CVS Health): Omnicare, owned by CVS Health, is the largest dedicated LTC pharmacy provider in the U.S. and works closely with consultant pharmacists on medication-management programs. It is both a potential channel partner for PGx Medical's Metabolic Validation Program and a potential strategic owner that could internalize PGx testing as part of its LTC medication-management offering.
- Quest Diagnostics: Quest Diagnostics offers pharmacogenomic testing services through its broad clinical laboratory network and serves LTC and outpatient prescribers nationwide. As a long-established incumbent with deep payor relationships and national logistics, Quest represents the highest-capacity competitive alternative to PGx Medical's Metabolic Validation Program.
- 23andMe: 23andMe is a broad, consumer-facing genetic testing company whose Health + Ancestry reports include pharmacogenomics insights for selected medications. While not focused on LTC, it normalizes consumer/patient familiarity with PGx results and can indirectly raise demand for clinical-grade PGx like PGx Medical's test.
- LabCorp (Laboratory Corporation of America): LabCorp is one of the two largest U.S. clinical reference laboratories and offers an extensive pharmacogenomics menu that overlaps with PGx Medical's CYP450 testing. As a broad incumbent, LabCorp already has payor contracts that PGx Medical depends on (e.g., Medicare), making it a critical competitive and channel threat for any LTC-focused PGx service.
Regional players
- PharMerica: PharMerica is a large long-term-care pharmacy operator serving skilled nursing, assisted living, and behavioral facilities. While not a PGx lab itself, it is the natural channel/distribution partner — or acquirer — for a company like PGx Medical whose entire customer base lives inside PharMerica-served facilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
PGx Medical social profiles
Digital presencePGx Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
PGx Medical leadership team
Management profileNumber of profiles
Profiles2 records
PGx Medical funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PGx Medical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PGx Medical
What does PGx Medical do?
PGx Medical delivers pharmacogenetic testing through its Metabolic Validation Program — a one-time cheek swab diagnostic that analyzes a patient's genetic profile (including CYP450 enzymes) to determine how they metabolize medications. The company sells this testing program along with implementation support, staff education, and ongoing consultation to long-term care communities, clinics, and consultant pharmacies serving elderly populations. The service is reimbursable under Medicare Part B and supported by Medicaid in select states, and is targeted at reducing adverse drug reactions, polypharmacy, falls, and antipsychotic overuse in older adults.
Is PGx Medical a public or private company?
PGx Medical is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was PGx Medical founded?
PGx Medical was founded in 2010. It employs 11 to 50 people.
Where is PGx Medical based?
PGx Medical is headquartered in Oklahoma City, United States, in the North America region.
How does PGx Medical make money?
Two revenue lines are on record. Medicare Part B Reimbursement is the primary driver. The others are consulting and Implementation Services.
Who are PGx Medical's main competitors?
Direct peers on record are Myriad Genetics (GeneSight), Genomind, Molecular Health, Coriell Life Sciences and YouScript / GenieMD. Broad incumbents are Omnicare (CVS Health), Quest Diagnostics, 23andMe and LabCorp (Laboratory Corporation of America). PharMerica is listed as a regional player.
Does PGx Medical have an API?
No public API is recorded for PGx Medical.
What industry is PGx Medical in?
PGx Medical's product category is Pharmacogenetic Testing Services. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HSABALAO, Pharmacogenomics-Informed Medication Optimization Support. Its NAICS code is 621511 and its SIC code is 8071.